Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Regulating the AI-enabled ecosystem for human therapeutics
23
Zitationen
3
Autoren
2025
Jahr
Abstract
Recent advances in artificial intelligence (AI) tools and techniques can revolutionize the discovery, development, manufacturing, and delivery of new medicines by reducing the time and cost involved. The biopharmaceutical industry is a highly regulated sector where robust regulatory oversight is essential to ensure human therapeutics' quality, efficacy, and safety. This Perspective examines the challenges of regulating AI-driven technologies in drug discovery and development. As AI is anticipated to play an unprecedented role in transforming drug development, the critical question is not whether to regulate these advancements but how to do so effectively. Here, we evaluate current global drug regulatory practices, discuss gaps and unknowns, and provide recommendations on addressing these issues to facilitate effective regulations of AI-driven innovation in the biopharmaceutical industry.
Ähnliche Arbeiten
Explainable Artificial Intelligence (XAI): Concepts, taxonomies, opportunities and challenges toward responsible AI
2019 · 8.402 Zit.
Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead
2019 · 8.270 Zit.
High-performance medicine: the convergence of human and artificial intelligence
2018 · 7.702 Zit.
Proceedings of the 19th International Joint Conference on Artificial Intelligence
2005 · 5.781 Zit.
Peeking Inside the Black-Box: A Survey on Explainable Artificial Intelligence (XAI)
2018 · 5.507 Zit.